NewAmsterdam Pharma(NASDAQ) NAMS

NewAmsterdam Pharma Company N.V. makes simple daily pills for high cholesterol. These medicines help patients who cannot use common heart treatments. The company also tests if these drugs help Alzheimer's patients.

What is NewAmsterdam Building?

• Obicetrapib Monotherapy: A once-daily pill that works as a cholesteryl ester transfer protein (CETP) inhibitor, which blocks a specific protein to help lower low-density lipoprotein cholesterol (LDL-C), or bad cholesterol.
• Fixed-Dose Combination: A single daily tablet that joins obicetrapib with ezetimibe, another type of cholesterol drug, to help patients who need more intensive treatment.
• Alzheimer's Research Program: A clinical effort exploring how the company's main drug might help patients who are in the early stages of Alzheimer's disease.
• Metabolic Syndrome Studies: Research into treating adults with type 2 diabetes or other metabolic issues who require better control of their cholesterol levels.

Steps Toward Global Expansion

• Partnered with A. Menarini International Licensing S.A. in June 2022 to develop and sell treatments across most of Europe.
• Submitted marketing authorization applications for obicetrapib to regulators in the United Kingdom and Switzerland for review during 2025.
• Raised $453.4 million in net proceeds through a public stock offering in December 2024 to support clinical trials and operations.
• Received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency in July 2026 for the use of two cholesterol-lowering therapies.

Designing More Convenient Care

NewAmsterdam Pharma targets the 75% of heart patients who prefer taking oral tablets instead of using injectable medicines. The company also focuses on reducing secondary markers of heart disease that standard treatments often miss.

The Latest Financial Facts

• Revenue was $3.7 million for the three-month period ended June 30, 2026, down 81% year over year due to the timing of license payments.
• Research and development expenses were $41.7 million for the three-month period ended June 30, 2026, up 52% year over year.
• The net loss for the three-month period ended June 30, 2026, was $64.1 million.
• Cash, cash equivalents, and marketable securities totaled $678.3 million as of June 30, 2026.
• Accumulated losses for the company reached $875.0 million as of June 30, 2026, due to ongoing clinical research.

Bottom Line

NewAmsterdam Pharma has evolved into a late-stage developer focused on providing oral alternatives for heart and brain diseases. Its strategy relies on large clinical trials and international partnerships to reach patients who are not served by current therapies.